Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31563787 | 0.85 | SMN1; SMN2 (0.47) | MEN1KMT2AGPR119POLB | |
| SCHEMBL2834188 | 0.83 | HPGDS (0.59) | GPR119 | |
| SCHEMBL10040512 | 0.80 | GPR119 (0.48) | MEN1KMT2AMMP13GPR119PTPN2 | |
| SCHEMBL16399664 | 0.80 | GPR119 (0.48) | KMT2AGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL22712368 | 0.78 | GRM5 (0.48) | MEN1KMT2AMMP13GPR119PTPN2 | |
| SCHEMBL4420449 | 0.77 | LMNA (0.61) | MEN1KMT2AGPR119HDAC4POLB | |
| SCHEMBL31515708 | 0.76 | CTSD (0.40) | MEN1KMT2AGPR119 | |
| SCHEMBL10040511 | 0.75 | GPR119 (0.57) | MMP13GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL1555350 | 0.74 | MMP13 (0.46) | MEN1KMT2AMMP13GPR119PTPN2 | |
| SCHEMBL12041540 | 0.74 | ALDH1A1 (0.61) | GPR119HDAC4PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | MEN1 3684/4885KMT2A 4715/4885MMP13 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.